Author:
Wiesmayr Silke,Webber Steven A.
Publisher
Springer Berlin Heidelberg
Reference31 articles.
1. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant. 2002; 2:993–8
2. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M, Hardesty RL, Dummer JS. Posstransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 1991;10: 877–86
3. Aull MJ, Buell JF, Trofe J, First MR, Alloway RR, Hanaway MJ, Wagoner L, Gross TG, Beebe T, Woodle ES. Experience with 274 cardiac transplant recipients with posttransplant lymphoprolif-erative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation. 2004;78:1676–82
4. Chen JM, Barr ML, Chadburn A, Frizzera G, Schenkel FA, Sciacca RR, Reison DS, Addonizio LJ, Rose EA, Knowles DM. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg. 1993;56:527–38
5. Crespo-Leiro MG, Alonso-Pulpón L, Vázquez de Prada JA, Almenar L, Arizón JM, Brossa V, Delgado JF, Fernandez-Yañez J, Manito N, Rábago G, Lage E, Roig E, Diaz-Molina B, Pascual D, Muñiz J. Malignancy after heart transplantation: incidence, prognosis and risk factors. Am J Transplant. 2008;8:1031–9